According to PharmaTimes, Merck & Co is planning to submit its new insomnia drug suvorexant for regulatory approval in the US in 2012.  Suvorexant is an investigational orexin receptor antagonist that has been investigated in two Phase III studies, the results of which are due to be presented at major medical meetings later this year. No further details are given in the report.